Risk Assessment in the Field of Oncology using Big Data

Abstract

Big data refers to massive volumes of information that are unmanageable by traditional systems and web-based applications. It surpasses traditional storage, processing, and analysis systems. The concept of “big data” incorporates not only just quantity but also efficiency and variety. In 2019, 1200 children are expected to die from cancer in the United States. In 2016, there were 1.7 hundred thousand advanced cases of adolescent malignancy. The FDA expects that first-in-child medicine authorization will take at least 6.5 years or half a decade. The need to speed up the throughput of pediatric oncology clinical studies is growing. RCTs have the potential to change a wider range of registries, allowing people to enroll in medical studies. Even though the number of patients enrolled in clinical trials has increased, there are still barriers to clinical trial enrollment. The standardization of data collection across trials and disease types could make medicinal cancer analysis easier, whereas the underlying causes and treatment duration correlation for radiation-induced cancer are uncertain, enormous breakthroughs in IGRT would help physicians better comprehend the ideas and process.

Ähnliche Arbeiten